The core retail business (OXXO Mexico) is performing well with accelerating margins, but Coca-Cola FEMSA's operating income decline and the 36.4% drop in adjusted net income are concerning. The non-renewal of the Colombia medication dispensing agreement adds uncertainty to the Health segment. Monitor the Q2 2026 conference call for guidance on Coca-Cola FEMSA margin recovery and the impact of the Cruz Verde contract termination. The elevated leverage (1.24x ND/EBITDA) from aggressive capital returns warrants watching.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 30 $118.24entry
- T+1 · 7mo ago +1.46%α +1.24% · $119.97
- T+5 · 6mo ago +3.32%α +1.60% · $122.17
- T+20 · 6mo ago +2.22%α −2.75% · $120.86
- T+60 · 4mo ago +11.76%α +8.66% · $132.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
FEMSA reported Q1 2026 results with consolidated revenue up 6.1% YoY to Ps. 207,784 million and operating income up 5.5% to Ps. 14,314 million, driven by strong performance at OXXO Mexico (revenue +8.3%, operating income +20.9%) and Americas & Mobility (+12.9% revenue). However, Coca-Cola FEMSA's operating income declined 2.3%, and Health operating income fell 14.2%. Net consolidated income surged 97.3% to Ps. 17,639 million, but excluding a one-time gain from the BradyPLUS/Imperial Dade merger, net income declined 36.4% to Ps. 5,688 million due to higher financing costs and FX losses. The company also announced a non-renewal of a medication dispensing agreement in Colombia and declared ordinary and extraordinary dividends.
Key Facts
- FEMSA consolidated revenue grew 6.1% YoY to Ps. 207,784 million in Q1 2026; on a comparable basis, revenue grew 8.5%.
- Consolidated income from operations increased 5.5% to Ps. 14,314 million; on a comparable basis, operating income grew 12.1%.
- OXXO Mexico revenue grew 8.3% to Ps. 74,424 million, with operating income up 20.9% to Ps. 5,629 million.
- Coca-Cola FEMSA revenue grew 1.1% to Ps. 70,925 million, but operating income declined 2.3% to Ps. 9,032 million.
- Health division revenue grew 0.9% to Ps. 22,175 million, but operating income declined 14.2% to Ps. 657 million.
- Consolidated net income was Ps. 17,639 million, up 97.3% YoY, but excluding a one-time gain from the BradyPLUS/Imperial Dade merger, net income was Ps. 5,688 million, a decline of 36.4%.
- Net Debt/EBITDA ex-KOF increased to 1.24x from 0.69x in 1Q25, reflecting cash outflows for dividends (Ps. 47,218 million) and share repurchases (Ps. 16,055 million) over the last twelve months.
- Cruz Verde Colombia notified EPS Sanitas of its decision not to renew the medication dispensing agreement under the Mandatory Health Plan, set to expire on September 30, 2026.
- Shareholders approved ordinary dividend of Ps. 4.7520 per BD Unit and extraordinary dividend of Ps. 8.0597 per BD Unit, payable in four installments.
Financial Impact
Consolidated revenue grew 6.1% to Ps. 207,784 million; operating income up 5.5% to Ps. 14,314 million; net income up 97.3% to Ps. 17,639 million (but down 36.4% excluding one-time gain). Coca-Cola FEMSA operating income down 2.3%.
Risk Factors
- Coca-Cola FEMSA operating income declined 2.3% YoY, with Mexico & Central America operating income down 17.4% due to excise tax increases and restructuring costs.
- Adjusted net income (ex-one-time gain) fell 36.4% due to higher financing costs, FX losses, and absence of discontinued operations income.
- Net debt/EBITDA ex-KOF rose to 1.24x from 0.69x a year ago, driven by large dividend and buyback payouts.
- Health division operating income declined 14.2%, and the non-renewal of the Cruz Verde Colombia medication dispensing agreement creates revenue risk for that segment.
- Europe same-store sales declined 2.7% YoY, indicating soft consumer trends in Germany.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-052276 |
| Document: tm2613197d1_6k.htm | 0001104659-26-052276 |
| Document: 0001104659-26-052276-index-headers.html | 0001104659-26-052276 |
| Document: 0001104659-26-052276-index.html | 0001104659-26-052276 |
| Document: 0001104659-26-052276.txt | 0001104659-26-052276 |
Track record
17 reports on FMX
2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +6.32% at T+20 after the Jun 8, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $132.53 to $130.72 Now $131.30 −0.93% ▼ −1.37% −1.01% vs SPY
- Oct 28, 202619d ago Press Release Bearish 5/10 Entry $123.70 to $124.28 Now $131.30 −6.14% ▼ −0.47% −0.85% vs SPY
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $123.70 to $124.28 Now $131.30 +6.14% ▲ +0.47% +0.85% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $127.98 to $129.03 Now $131.30 +2.59% ▲ +0.82% +2.00% vs SPY
- Oct 1, 20266w ago Press Release Neutral 1/10 Entry $115.68 Now $131.30 +13.50% No price data
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $117.71 to $119.62 Now $131.30 +11.55% ▲ +1.62% +1.08% vs SPY
- Sep 14, 20269w ago Press Release Neutral 4/10 Entry $121.26 to $121.60 Now $131.30 +8.28% ▲ +0.28% +0.74% vs SPY
- Sep 14, 20269w ago 6-K Bullish 4/10 Entry $121.26 to $121.60 Now $131.30 +8.28% ▲ +0.28% +0.74% vs SPY
- Jun 29, 202620w ago Press Release Neutral 1/10 Entry $127.90 to $128.11 Now $131.30 +2.66% ▲ +0.16% +0.30% vs SPY
- Jun 8, 202623w ago 6-K Bullish 5/10 Entry $122.51 to $122.20 Now $131.30 +7.17% ▼ −0.25% +0.04% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers